MAM
BLCM

Meeder Asset Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Meeder Asset Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9
Closed -$1K – 1840
2017
Q3 		$1K Sell
9
-2
-18% -$210 ﹤0.01% 1582
2017
Q2 		$1K Sell
11
-22
-67% -$2.73K ﹤0.01% 1572
2017
Q1 		$4K Buy
33
+27
+450% +$3.54K ﹤0.01% 1200
2016
Q4 		$1K Buy
+6
New +$1.06K ﹤0.01% 966

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Meeder Asset Management's BLCM Position: Q4 2017 in Review

Meeder Asset Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2017, closing a stake of 9 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in BLCM in Q4 2016 and held it in 4 quarters. The position peaked at $4K in Q1 2017. 91 funds tracked by Wall St. Rank hold BLCM as of Q4 2017.

  • Meeder Asset Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Meeder Asset Management sold 9 Bellicum Pharmaceuticals, Inc. shares in Q4 2017, an estimated $1K.
  • Meeder Asset Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2016 and held it in 4 quarters.
  • Meeder Asset Management's Bellicum Pharmaceuticals, Inc. position peaked at $4K in Q1 2017.
  • 91 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2017.

Based on Meeder Asset Management's 13F filing for Q4 2017, filed 2 Feb 2018.